Beyond direct IFN blockade, inhibition of downstream JAK–STAT signaling has been successfully applied in monogenic interferonopathies such as SAVI, where ruxolitinib and baricitinib ameliorated inflammatory and pulmonary manifestations, though these drugs have broader immunological effects beyond IFN signaling [181]. The gene discussed is IFNA1; the disease is STING-associated vasculopathy with onset in infancy.